Open-Label Randomized Dual-Arm Fixed-Dose Study of Oral Tofacitinib for Moderate to Severe Alopecia Areata*

2016 to 2018
Investigator-Initiated Research Grant Opportunities
Justin Ko, MD, MBA, Principal Investigator
Stanford University

*Funding conditional on approval from the drug company to provide the compound free of charge or procurement of funding from alternative sources for the drug. 


If successful, this study will lead to better understanding of the optimal dose of the drug, and molecular profiling could provide novel insights into clinical response. 


1) To compare the efficacy, safety and tolerability of tofacitinib 5 mg twice daily dosing to 10 mg twice daily dosing for a 24-week regimen, with 32 patients enrolled in each arm; and 2) To collect blood and tissue samples for molecular profiling to assess clinical response and durability of treatment.